Low-Dose Aspirin Linked to Lower Odds of Metastatic Colorectal Cancer in British Journal of Cancer Study

Regular low-dose aspirin use is associated with a 14 percent overall reduction in the adjusted odds of synchronous distant metastasis among colorectal cancer patients at diagnosis, according to a nationwide Swedish study.

The British Journal of Cancer featured an investigation that reviewed health register records for 81,269 colorectal cancer patients gathered across a fourteen-year period via the Colorectal Cancer Database Sweden (CRCBaSe). Patients actively taking prescribed low-dose aspirin showed notable reductions in metastatic risk, though the protective association varied significantly by tumor location.

Colorectal cancer stands as the third most common malignancy and the second leading cause of cancer-related mortality globally. Projections anticipate a 71 percent surge in total global burden by 2045, and approximately 20 percent of patients present with distant metastatic disease at initial diagnosis. Five-year relative survival remains near 60 percent worldwide, driving ongoing investigation into inexpensive, preventative interventions.

Aspirin could stop some cancers from spreading, study finds

The inverse association between aspirin and metastasis appeared most pronounced among individuals diagnosed with right-sided colon tumors. Current aspirin use was linked to a 21 percent reduction in metastatic odds for right-sided lesions, while past users also exhibited a corresponding risk reduction that persisted independently of exposure duration.

Conversely, this protective correlation failed to consistently apply to left-sided colon cancers, demonstrating significant anatomical variation in how aspirin interacts with colorectal cancer progression.

Data Sources and Cohort Selection in Swedish Registries

The study identified all people aged 18 and older who were diagnosed with primary stage I through IV colorectal cancer from 2008 to 2021. To preserve diagnostic accuracy, the study group left out patients with prior colorectal tumors, individuals diagnosed with a different cancer within the five years before their colorectal diagnosis, and cases missing documented tumor sites.

Linkages using Sweden’s unique personal identification numbers enabled complete tracing through the National Patient Register, the Swedish Cancer Register, and the Longitudinal Integrated Database for Health Insurance and Labour Market Studies.

Low-Dose Aspirin Linked to Lower Odds of Metastatic Colorectal Cancer in British Journal of Cancer Study
Photo: bioengineer.org

Clinical and pathological information regarding rectal cancer patients has been compiled by the Swedish Colorectal Cancer Registry since 1995, and for colon cancer patients since 2007. Assessment of pharmaceutical exposure was established through the Swedish Prescribed Drug Register, tracking automated dispensations across community pharmacies with complete national capture since July 2005. In Sweden, low-dose aspirin in 75 mg or 160 mg strengths is restricted to medical prescription, preventing untracked over-the-counter acquisition.

Taking at least 365 dispensed tablets before a cancer diagnosis counted as exposure, which equals a minimum of twelve months of accumulated medicine based on a standard assumed daily dose of one pill per day. Patients meeting this threshold were categorized as current users if dispensation occurred within two years of diagnosis, or past users if dispensations did not reach that window immediately prior to cancer detection.

Lower Aspirin dosage may lower cancer risk

Low-Dose Aspirin Tied to Lower Metastatic Odds in Right-Sided Tumors

  • The protective association observed in the registry data pertains specifically to prescribed low-dose formulations (75 mg or 160 mg) rather than high-dose analgesic use.
  • Anatomical differences in tumor location, such as right-sided versus left-sided colon lesions, influence how aspirin interacts with disease progression.
Analysis Parameter Cohort Specification Observed Association
Right-Sided Colon Tumors Subgroup analysis 21% reduction in metastatic odds for current aspirin users
Exposure Threshold ≥365 dispensed low-dose pills Minimum 12 months of cumulative medication duration

Mouse Models and Trials Show Conflicting Aspirin Metastasis Results

Mouse experiments demonstrating decreased metastasis first connected aspirin to cancer biology in 1972, and human epidemiological studies showing a lower risk of colorectal cancer followed in 1988. However, randomized trials assessing aspirin in cardiovascular prevention have yielded conflicting results. Despite the ASPREE study on older adults showing an elevated risk of new metastatic cancer among aspirin consumers, combined evaluations of earlier prevention trials revealed a 31 percent drop in metastatic adenocarcinoma.

These discrepancies prompted large-scale observational register studies to clarify the compound’s real-world impact across unselected populations. The current Swedish analysis controlled for potential confounding factors including age, sex, year of diagnosis, education level, diabetes, hypertension, cardiovascular disease, inflammatory bowel disease, and gastrointestinal bleeding.

The British Journal of Cancer, which published the Swedish register study, was founded in 1947 by the British Empire Cancer Campaign, the charity that later became Cancer Research UK. For decades the journal was owned by that charity and published in partnership with Nature before Springer Nature acquired full ownership in 2021.

References

British Journal of Cancer – Population-based cohort study data on pharmaceutical exposure and cancer characteristics.

  • Colorectal Cancer Database Sweden (CRCBaSe) – Nationwide health and demographic register linkages.
Photo of author

Health Desk

Health Desk at Archyde.

Light the World Giving Machines Open Third Year at Scheels in Sparks